2Schneider J, Neu K, Grimm H , et al. Tumor M2-pyruvate kinasein lung cancer patients: immunohistochemical detection and disease monitoring[J]. Anticaneer Res,2002,22(1A) :3111.318.
3Stefano Elia, Renato Massoud, Gianluca Guggino. et al. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures [ J]. European Journal of Cardio-thoracic Surgery 33 (2008) :723 - 727.
4Oremek G, Kukshaite R, Sapoutzis N, Ziolkovski P. The significance of TU M2-PK tumor marker for lung cancer diagnostics [ J ]. Klin Med ( Mosk), 2007,85 (7) :56 - 8.
5Schneider J, Neu K, Velcovsky HG, et al. Tumor M2-pyruvate kinase in the follow up of inoperable lung cancer patients :a pilotstudy [ J ]. Cancer Iett,2003,193( 1 ) :91 -98.
6Schneider J, Pehri G. Bitterlieh N. et al. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients [ J ]. Clin Exp Med,2003,2 ( 4 ) : 185 -191.
8Kumar Y, Tapuria N, Kimani N, et al. Tumor M2-pyiuvate kinase a gastrointestinal cancer marke [ J ]. Eur J Gastroen-terol Hepatol, 2007,19 (3) :265 - 267.
9Ewald N, Schaller M, Bayer M, et al. Fecal pyruvate kinase-M2 ( tumorM2-PK) measurement: a new screening concep t for colorectal cancer[ J]. Anticancer Res ,2007,27 (4A) : 1949 - 1952.
10Lucia C. FryKlaus Monkemtuller. Molecular markers of pancreatic cancer: development and clinical relevance[J]. Langenbecks Arch Surg,2008 ,393 :883 - 890.
6Schneider J, Peltri G, Bitterlleh N, et al. Fuzzy logiebased tumor marker profiles improved sensitivity of the detection of progression in small -cell lung cancer patients. Clin Exp Med. 2003,2(4) :185.
